1
|
Yamaguchi K, Horie C, Takane K, Ikenoue T, Nakagawa S, Isobe Y, Ota Y, Ushiku T, Tanaka M, Fujishiro J, Hoshino N, Arisue A, Nishizuka S, Aikou S, Shida D, Furukawa Y. Identification of odontogenic ameloblast associated as a novel target gene of the Wnt/β-catenin signaling pathway. Cancer Sci 2023; 114:948-960. [PMID: 36382598 PMCID: PMC9986071 DOI: 10.1111/cas.15657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Revised: 10/31/2022] [Accepted: 11/09/2022] [Indexed: 11/17/2022] Open
Abstract
The Wnt/β-catenin signaling pathway plays a key role in development and carcinogenesis. Although some target genes of this signaling have been identified in various tissues and neoplasms, the comprehensive understanding of the target genes and their roles in the development of human cancer, including hepatoma and colorectal cancer remain to be fully elucidated. In this study, we searched for genes regulated by the Wnt signaling in liver cancer using HuH-7 hepatoma cells. A comparison of the expression profiles between cells expressing an active form of mutant β-catenin and cells expressing enhanced green fluorescent protein (EGFP) identified seven genes upregulated by the mutant β-catenin gene (CTNNB1). Among the seven genes, we focused in this study on ODAM, odontogenic, ameloblast associated, as a novel target gene. Interestingly, its expression was frequently upregulated in hepatocellular carcinoma, colorectal adenocarcinoma, and hepatoblastoma. We additionally identified a distant enhancer region that was associated with the β-catenin/TCF7L2 complex. Further analyses revealed that ODAM plays an important role in the regulation of the cell cycle, DNA synthesis, and cell proliferation. These data may be useful for clarification of the main molecular mechanism(s) underlying these cancers.
Collapse
Affiliation(s)
- Kiyoshi Yamaguchi
- Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Chiaki Horie
- Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Kiyoko Takane
- Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Tsuneo Ikenoue
- Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Saya Nakagawa
- Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Yumiko Isobe
- Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Yasunori Ota
- Department of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Tetsuo Ushiku
- Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Mariko Tanaka
- Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Jun Fujishiro
- Department of Pediatric Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Noriko Hoshino
- Department of Pediatric Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Atsuhiro Arisue
- Department of Surgery, Iwate Medical University School of Medicine, Yahaba, Japan
| | - Satoshi Nishizuka
- Division of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, Yahaba, Japan
| | - Susumu Aikou
- Division of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Dai Shida
- Division of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Yoichi Furukawa
- Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
2
|
Zhu S, Xiang C, Charlesworth O, Bennett S, Zhang S, Zhou M, Kujan O, Xu J. The versatile roles of odontogenic ameloblast-associated protein in odontogenesis, junctional epithelium regeneration and periodontal disease. Front Physiol 2022; 13:1003931. [PMID: 36117697 PMCID: PMC9478555 DOI: 10.3389/fphys.2022.1003931] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Accepted: 08/09/2022] [Indexed: 11/13/2022] Open
Abstract
Junctional epithelium (JE) is a vital epithelial component which forms an attachment to the tooth surface at the gingival sulcus by the adhesion of protein complexes from its basal layer. Disruption of the JE is associated with the development of gingivitis, periodontal disease, and alveolar bone loss. Odontogenic ameloblast-associated (ODAM) is comprised of a signal peptide and an ODAM protein with 12 putative glycosylation sites. It is expressed during odontogenesis by maturation stage ameloblasts and is incorporated into the enamel matrix during the formation of outer and surface layer enamel. ODAM, as a secreted protein which is accumulated at the interface between basal lamina and enamel, mediates the adhesion of the JE to the tooth surface; and is involved with extracellular signalling of WNT and ARHGEF5-RhoA, as well as intracellular signalling of BMP-2-BMPR-IB-ODAM. ODAM is also found to be highly expressed in salivary glands and appears to have implications for the regulation of formation, repair, and regeneration of the JE. Bioinformatics and research data have identified the anti-cancer properties of ODAM, indicating its potential both as a prognostic biomarker and therapeutic target. Understanding the biology of ODAM will help to design therapeutic strategies for periodontal and dental disorders.
Collapse
Affiliation(s)
- Sipin Zhu
- Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China
- Molecular Lab, School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia
- *Correspondence: Sipin Zhu, ; Jiake Xu,
| | - Chuan Xiang
- Molecular Lab, School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia
- Department of Orthopaedics, The Second Hospital of Shanxi Medical University, Taiyuan, China
| | - Oscar Charlesworth
- Molecular Lab, School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia
| | - Samuel Bennett
- Molecular Lab, School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia
| | - Sijuan Zhang
- Affiliated Stomatology Hospital of Guangzhou Medical University, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerative Medicine, Guangzhou, China
| | - Maio Zhou
- Department of Stomatology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Science, Guangzhou, China
| | - Omar Kujan
- UWA Dental School, The University of Western Australia, Perth, Western Australia, Australia
| | - Jiake Xu
- Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China
- Molecular Lab, School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia
- *Correspondence: Sipin Zhu, ; Jiake Xu,
| |
Collapse
|
3
|
Starzyńska A, Sejda A, Adamska P, Marvaso G, Sakowicz-Burkiewicz M, Adamski Ł, Jereczek-Fossa BA. Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review. Arch Med Sci 2021; 17:207-217. [PMID: 33488873 PMCID: PMC7811327 DOI: 10.5114/aoms.2020.100780] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Accepted: 05/25/2018] [Indexed: 12/14/2022] Open
Abstract
Over 260,000 (2013) new oral squamous cell carcinoma (OSCC) cases are reported annually worldwide. Despite development in OSCC management, the outcome is still unsatisfactory. Identification of new molecular markers may be of use in prevention, prognosis, and choice of an appropriate therapy. The intracellular molecular signalling pathway of phosphatidyl-inositol-3-kinase is involved in the process of cell growth, differentiation, migration, and survival. The main components of this pathway: PIK3CA (phosphatidylinositol-4,5-bisphosphate-3-kinase catalytic subunit α), PTEN (phosphatase and tensin homologue deleted on chromosome 10), and AKT (serine-threonine kinase) are potential objects of research when introducing new therapeutic agents. The aim of this paper is to evaluate the PIK3CA, PTEN, and AKT gene mutations as prognostic factors in OSCC and to describe their role in aggressive disease progression. This is crucial for oral cancer biology understanding and for indicating which direction new clinical treatments should take.
Collapse
Affiliation(s)
- Anna Starzyńska
- Department of Oral Surgery, Medical University of Gdansk, Gdansk, Poland
| | - Aleksandra Sejda
- Department of Pathomorphology, University of Warmia and Mazury, Olsztyn, Poland
| | - Paulina Adamska
- Department of Oral Surgery, Medical University of Gdansk, Gdansk, Poland
| | - Giulia Marvaso
- Department of Radiotherapy, European Institute of Oncology, IRCCS, Milan, Italy
- Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy
| | | | - Łukasz Adamski
- Department of Oral Surgery, Medical University of Gdansk, Gdansk, Poland
| | - Barbara A. Jereczek-Fossa
- Department of Radiotherapy, European Institute of Oncology, IRCCS, Milan, Italy
- Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy
| |
Collapse
|
4
|
Bell AH, Prieto VG, Ferrarotto R, Goepfert RP, Myers JN, Weber R, Bell D. Magnifying glass on spiradenoma and cylindroma histogenesis and tumorigenesis using systematic transcriptome analysis. Ann Diagn Pathol 2019; 41:14-23. [PMID: 31128548 DOI: 10.1016/j.anndiagpath.2019.04.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Accepted: 04/28/2019] [Indexed: 10/26/2022]
Abstract
Spiradenoma and cylindroma are related sweat gland tumors. To delineate their histogenesis, gene profiles, and their potential drivers, we performed a whole-transcriptome sequencing analysis of fourteen samples of spiradenoma/cylindroma in comparison to normal samples. A total of 12 spiradenomas, 5 cylindromas, 3 hybrid spiradenomas/cylindromas and 2 adnexal carcinomas were included in this study. 1335 characteristic genes and transcripts expressed over all 14 spiradenoma/cylindroma tumors were identified, and two groups of expression profiles were observed. Highest upregulated top 7 gene signatures characterized benign tumors with developmental and differentiation related genes, and carcinomas with top 7 genes mainly related to signaling, reorganization and metabolism of membranes. Immunohistochemistry of protein expressions validated 4 upregulated genes (ODAM, HOXB13, MYB and SOX10) considered important and as potential biomarkers for spiradenomas and cylindromas. We further compared the transcriptome of eccrine adnexal tumors with the transcriptome of adenoid cystic carcinoma (ACC) to identify the overlapping genes that may indicate histogenesis. There were 36 specific genes overlapping between adnexal carcinomas and the epithelial-dominant subtype of ACC, and 27 specific genes overlapping benign adnexal tumors with the myoepithelial-dominant subtype of ACC, At this point there is no known specific biomarker to aid in the diagnosis of eccrine spiradenoma and cylindroma in small samples or biopsies within the context of morphological overlap with ACC. In conclusion, spiradenomas and cylindromas are characterized by overexpressed developmental genes, where LHX2 and activated WNT signaling possibly drive associated carcinomas.
Collapse
Affiliation(s)
- Achim H Bell
- Department of Research Pathology, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
| | - Victor G Prieto
- Department of Pathology, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
| | - Renata Ferrarotto
- Department of Thoracic Head and Neck Oncology, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
| | - Ryan P Goepfert
- Department of Head and Neck Surgery, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
| | - Jeffrey N Myers
- Department of Head and Neck Surgery, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
| | - Randal Weber
- Department of Head and Neck Surgery, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
| | - Diana Bell
- Department of Pathology, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; Department of Head and Neck Surgery, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
| |
Collapse
|
5
|
Désert R, Rohart F, Canal F, Sicard M, Desille M, Renaud S, Turlin B, Bellaud P, Perret C, Clément B, Lê Cao KA, Musso O. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 2017; 66:1502-1518. [PMID: 28498607 DOI: 10.1002/hep.29254] [Citation(s) in RCA: 76] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Revised: 04/03/2017] [Accepted: 05/03/2017] [Indexed: 12/25/2022]
Abstract
UNLABELLED Hepatocellular carcinomas (HCCs) exhibit a diversity of molecular phenotypes, raising major challenges in clinical management. HCCs detected by surveillance programs at an early stage are candidates for potentially curative therapies (local ablation, resection, or transplantation). In the long term, transplantation provides the lowest recurrence rates. Treatment allocation is based on tumor number, size, vascular invasion, performance status, functional liver reserve, and the prediction of early (<2 years) recurrence, which reflects the intrinsic aggressiveness of the tumor. Well-differentiated, potentially low-aggressiveness tumors form the heterogeneous molecular class of nonproliferative HCCs, characterized by an approximate 50% β-catenin mutation rate. To define the clinical, pathological, and molecular features and the outcome of nonproliferative HCCs, we constructed a 1,133-HCC transcriptomic metadata set and validated findings in a publically available 210-HCC RNA sequencing set. We show that nonproliferative HCCs preserve the zonation program that distributes metabolic functions along the portocentral axis in normal liver. More precisely, we identified two well-differentiated, nonproliferation subclasses, namely periportal-type (wild-type β-catenin) and perivenous-type (mutant β-catenin), which expressed negatively correlated gene networks. The new periportal-type subclass represented 29% of all HCCs; expressed a hepatocyte nuclear factor 4A-driven gene network, which was down-regulated in mouse hepatocyte nuclear factor 4A knockout mice; were early-stage tumors by Barcelona Clinic Liver Cancer, Cancer of the Liver Italian Program, and tumor-node-metastasis staging systems; had no macrovascular invasion; and showed the lowest metastasis-specific gene expression levels and TP53 mutation rates. Also, we identified an eight-gene periportal-type HCC signature, which was independently associated with the highest 2-year recurrence-free survival by multivariate analyses in two independent cohorts of 247 and 210 patients. CONCLUSION Well-differentiated HCCs display mutually exclusive periportal or perivenous zonation programs. Among all HCCs, periportal-type tumors have the lowest intrinsic potential for early recurrence after curative resection. (Hepatology 2017;66:1502-1518).
Collapse
Affiliation(s)
- Romain Désert
- INSERM, INRA, Univ Rennes, CHU Rennes, Nutrition Metabolisms and Cancer (NuMeCan), CRB-Santé, Biosit, Biogenouest, UBL, Rennes, France
| | - Florian Rohart
- Diamantina Institute and Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia
| | - Frédéric Canal
- INSERM, CNRS, Université de Paris Descartes, Sorbonne Paris Cité, Institut Cochin, Paris, France
| | - Marie Sicard
- INSERM, INRA, Univ Rennes, CHU Rennes, Nutrition Metabolisms and Cancer (NuMeCan), CRB-Santé, Biosit, Biogenouest, UBL, Rennes, France
| | - Mireille Desille
- INSERM, INRA, Univ Rennes, CHU Rennes, Nutrition Metabolisms and Cancer (NuMeCan), CRB-Santé, Biosit, Biogenouest, UBL, Rennes, France
| | - Stéphanie Renaud
- INSERM, INRA, Univ Rennes, CHU Rennes, Nutrition Metabolisms and Cancer (NuMeCan), CRB-Santé, Biosit, Biogenouest, UBL, Rennes, France
| | - Bruno Turlin
- INSERM, INRA, Univ Rennes, CHU Rennes, Nutrition Metabolisms and Cancer (NuMeCan), CRB-Santé, Biosit, Biogenouest, UBL, Rennes, France
| | - Pascale Bellaud
- INSERM, INRA, Univ Rennes, CHU Rennes, Nutrition Metabolisms and Cancer (NuMeCan), CRB-Santé, Biosit, Biogenouest, UBL, Rennes, France
| | - Christine Perret
- INSERM, CNRS, Université de Paris Descartes, Sorbonne Paris Cité, Institut Cochin, Paris, France
| | - Bruno Clément
- INSERM, INRA, Univ Rennes, CHU Rennes, Nutrition Metabolisms and Cancer (NuMeCan), CRB-Santé, Biosit, Biogenouest, UBL, Rennes, France
| | - Kim-Anh Lê Cao
- Diamantina Institute and Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia
| | - Orlando Musso
- INSERM, INRA, Univ Rennes, CHU Rennes, Nutrition Metabolisms and Cancer (NuMeCan), CRB-Santé, Biosit, Biogenouest, UBL, Rennes, France
| |
Collapse
|
6
|
Yu M, Mu Y, Qi Y, Qin S, Qiu Y, Cui R, Zhong M. Odontogenic ameloblast-associated protein (ODAM) inhibits human colorectal cancer growth by promoting PTEN elevation and inactivating PI3K/AKT signaling. Biomed Pharmacother 2016; 84:601-607. [DOI: 10.1016/j.biopha.2016.09.076] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Revised: 09/20/2016] [Accepted: 09/20/2016] [Indexed: 11/25/2022] Open
|
7
|
Cai L, Li J, Zhang X, Lu Y, Wang J, Lyu X, Chen Y, Liu J, Cai H, Wang Y, Li X. Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma. Oncotarget 2016; 6:7838-50. [PMID: 25691053 PMCID: PMC4480720 DOI: 10.18632/oncotarget.3046] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2014] [Accepted: 01/07/2015] [Indexed: 12/26/2022] Open
Abstract
Epstein-Barr virus (EBV) infection is a major etiological factor for nasopharyngeal carcinoma (NPC). Several EBV-encoded BART miRNAs have been associated with viral latency, immune escape, cell survival, cell proliferation and apoptosis. Here, we report that EBV-miR-BART7-3p, an EBV-encoded BART miRNA highly expressed in NPC, was correlated with cell-cycle progression in vitro and increased tumor formation in vivo. This viral miRNA stimulated the PTEN/PI3K/Akt pathway and induced c-Myc and c-Jun. Knockdown of PTEN mimicked EBV-miR-BART7-3p-induced tumorigenic phenotype. Based on these results, we conducted a therapeutic experiment by using gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p. Silencing of EBV-miR-BART7-3p reduced tumor growth in animal model. We conclude that EBV-miR-BART7-3p favors carcinogenesis, representing a potential target for miRNA-based therapy.
Collapse
Affiliation(s)
- Longmei Cai
- Cancer Research Institute, Southern Medical University, Guangzhou 510515, China
| | - Jinbang Li
- Cancer Research Institute, Southern Medical University, Guangzhou 510515, China
| | - Xiaona Zhang
- Cancer Research Institute, Southern Medical University, Guangzhou 510515, China.,The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China
| | - Yaoyong Lu
- Cancer Research Institute, Southern Medical University, Guangzhou 510515, China.,Department of Radiation Oncology, Gaozhou People's Hospital, Gaozhou 525200, China
| | - Jianguo Wang
- Cancer Research Institute, Southern Medical University, Guangzhou 510515, China
| | - Xiaoming Lyu
- Cancer Research Institute, Southern Medical University, Guangzhou 510515, China.,Central Medical Laboratory, The Third Affiliated Hospital, Southern Medical University, Guangzhou 510515, China
| | - Yuxiang Chen
- Cancer Research Institute, Southern Medical University, Guangzhou 510515, China
| | - Jinkun Liu
- School of Chinese Traditional Medicine, Southern Medical University, Guangzhou 510515, China
| | - Hongbing Cai
- School of Chinese Traditional Medicine, Southern Medical University, Guangzhou 510515, China
| | - Ying Wang
- Cancer Research Institute, Southern Medical University, Guangzhou 510515, China
| | - Xin Li
- Cancer Research Institute, Southern Medical University, Guangzhou 510515, China
| |
Collapse
|
8
|
McLoughlin J, Nodit L, Heidel RE, Van Meter S, Macy S, Kestler D. The clinical correlation of phosphatase and tensin homolog on chromosome 10, phosphorylation of AKT to an activated state, and odontogenic ameloblast-associated protein in gastrointestinal stromal tumors. J Surg Res 2016; 202:403-12. [PMID: 27229116 DOI: 10.1016/j.jss.2016.01.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2015] [Revised: 11/23/2015] [Accepted: 01/11/2016] [Indexed: 11/18/2022]
Abstract
BACKGROUND Approximately 15% of gastrointestinal stromal tumors (GISTs) will not respond to tyrosine kinase inhibitors and drug resistance can develop over time. For refractory tumors, additional therapies are needed. Odontogenic ameloblast-associated protein (ODAM) is expressed in some epithelial malignancies and can correlate with clinical outcomes. This study evaluated ODAM and its relationship to phosphatase and tensin homolog on chromosome 10 (PTEN) and phosphorylation of AKT to an activated state (pAKT) in GISTs. MATERIALS AND METHODS Ninety-five distinct tumor specimens from 79 patients were identified. Morphologic features and clinical data were recorded for all tumors. Risk of recurrence was calculated using the Memorial Sloan-Kettering nomogram. Immunohistochemistry was performed using antibodies to ODAM, PTEN, and pAKT. Immunoreactivity was assessed for both cytoplasmic and nuclear expression. Staining patterns were correlated with clinical outcomes. RESULTS Increasing cytoplasmic ODAM staining correlated with a lower recurrence score (P = 0.002), a lower mitotic rate (P = 0.0001), and smaller tumor size (P = 0.038). Increasing pAKT cytoplasmic staining correlated with a higher recurrence score (P = 0.037) and a higher mitotic rate (P = 0.036). ODAM and pAKT expression in the nucleus was associated with tumor origin. PTEN nuclear expression increased with increasing mitotic rate. pAKT expression increased in the cytoplasm and nucleus in high-risk tumors. CONCLUSIONS Risk of recurrence correlated with cytoplasmic expression of ODAM and pAKT, whereas nuclear expression did not predict recurrence. The staining pattern for ODAM and pAKT in the cytoplasm may further clarify the risk of recurrence beyond the available nomograms. The increased expression of pAKT in the cytoplasm and nucleus of high-risk tumors suggests a potential target for systemic therapy.
Collapse
Affiliation(s)
- James McLoughlin
- Department of Surgery, University of Tennessee Medical Center, Knoxville, Tennessee.
| | - Laurentia Nodit
- Department of Pathology, University of Tennessee Medical Center, Knoxville, Tennessee
| | - R Eric Heidel
- Department of Biostatistics, University of Tennessee Medical Center, Knoxville, Tennessee
| | - Stuart Van Meter
- Department of Pathology, University of Tennessee Medical Center, Knoxville, Tennessee
| | - Sallie Macy
- University of Tennessee Medical Center, Graduate School of Medicine, Knoxville, Tennessee
| | - Daniel Kestler
- University of Tennessee Medical Center, Graduate School of Medicine, Knoxville, Tennessee
| |
Collapse
|
9
|
Luo Y, Wu JY, Hou GL, Lu MH, Shi Z, Di JM. ODAM is a predictor for biomedical recurrence and inhibits the migration and invasion of prostate cancer. Am J Transl Res 2016; 8:670-9. [PMID: 27158359 PMCID: PMC4846916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Accepted: 01/04/2016] [Indexed: 06/05/2023]
Abstract
Odontogenic ameloblast associated protein (ODAM) is a protein contributed to cell adhesion and has been shown to express in normal prostate tissue, but the expression and significance of ODAM in prostate cancer remain unknown. In this study, we detected the protein expressions of ODAM in 88 prostate cancer tissues with immunohistochemical staining, and found that 53 cases (60.2%) was high expression of ODAM, which was shown in the cytoplasm and paranuclear regions. Furthermore, low expression of ODAM was significantly correlated with lymph node metastasis, preoperative PSA and Gleason score, but not with mean age, follow-up duration, PSM rate and distribution of pathological T stage. Additionally, our results of multivariate analysis showed that low ODAM expression was an independent predictor of biomedical recurrence, while the positive lymph node metastasis, Gleason score, and preoperative PSA were not the independent risks for biomedical recurrence. Overexpression of ODAM did not inhibit the growth of prostate cancer cells PC3, but significant suppressed their invasion and migration with decrease of the protein levels of MMP-2. These results suggest that ODAM is a predictor for biomedical recurrence and inhibits the migration and invasion of prostate cancer.
Collapse
Affiliation(s)
- Yun Luo
- Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen UniversityGuangzhou, Guangdong, China
| | - Jie-Ying Wu
- Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen UniversityGuangzhou, Guangdong, China
| | - Guo-Liang Hou
- Department of Urology, Foshan First Municipal People’s HospitalFoshan 528000, China
| | - Min-Hua Lu
- Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen UniversityGuangzhou, Guangdong, China
| | - Zhi Shi
- Department of Cell Biology & Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan UniversityGuangzhou, Guangdong, China
| | - Jin-Ming Di
- Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen UniversityGuangzhou, Guangdong, China
| |
Collapse
|
10
|
Lee HK, Choung HW, Yang YI, Yoon HJ, Park IA, Park JC. ODAM inhibits RhoA-dependent invasion in breast cancer. Cell Biochem Funct 2015; 33:451-61. [PMID: 26358398 DOI: 10.1002/cbf.3132] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2015] [Revised: 06/16/2015] [Accepted: 06/22/2015] [Indexed: 11/06/2022]
Abstract
Odontogenic ameloblast-associated protein (ODAM) contributes to cell adhesion. In human cancer, ODAM is down-regulated, and the overexpression of ODAM results in a favourable prognosis; however, the molecular mechanisms underlying ODAM-mediated inhibition of cancer invasion and metastasis remain unclear. Here, we identify a critical role for ODAM in inducing cancer cell adhesion. ODAM induced RhoA activity and the expression of downstream factors, including Rho-associated kinase (ROCK). ODAM-mediated RhoA signalling resulted in actin filament rearrangement by activating PTEN and inhibiting the phosphorylation of AKT. When ODAM is overexpressed in MCF7 breast cancer cells and AGS gastric cancer cells that activate RhoA at high levels, it decreases motility, increases adhesion and inhibits the metastasis of MCF7 cells. Conversely, depletion of ODAM in cancer cells inhibits Rho GTPase activation, resulting in increased cancer migration and invasion. These results suggest that ODAM expression in cells maintains their adhesion, resulting in the prevention of their metastasis via the regulation of RhoA signalling in breast cancer cells. SIGNIFICANCE Breast cancer represents the first most frequent cancer, and the ratio of mortality is high in women. Of utmost importance for reducing risk by breast cancer are their anti-invasion mechanisms, particularly in the non-invasive cancer cells because metastasis is the principal cause of death among cancer patients. ODAM induced RhoA activity. ODAM-mediated RhoA signalling resulted in actin filament rearrangement, increased cell adhesion and inhibited the migration/invasion of MCF7 cells. These results suggest that ODAM expression maintains their adhesion, resulting in the prevention of their metastasis via the regulation of RhoA signalling in breast cancer cells.
Collapse
Affiliation(s)
- Hye-Kyung Lee
- Department of Oral Histology-Developmental Biology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea
| | - Han-Wool Choung
- Department of Oral Histology-Developmental Biology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea
| | - Young-Il Yang
- Paik Institute Clinical Research, Inje University, Busan, Republic of Korea
| | - Hye-Jung Yoon
- Department of Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea
| | - In Ae Park
- Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Joo-Cheol Park
- Department of Oral Histology-Developmental Biology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea
| |
Collapse
|
11
|
Nguyen M, Boutinaud M, Pétridou B, Gabory A, Pannetier M, Chat S, Bouet S, Jouneau L, Jaffrezic F, Laloë D, Klopp C, Brun N, Kress C, Jammes H, Charlier M, Devinoy E. DNA methylation and transcription in a distal region upstream from the bovine AlphaS1 casein gene after once or twice daily milking. PLoS One 2014; 9:e111556. [PMID: 25369064 PMCID: PMC4219721 DOI: 10.1371/journal.pone.0111556] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Accepted: 10/02/2014] [Indexed: 12/31/2022] Open
Abstract
Once daily milking (ODM) induces a reduction in milk production when compared to twice daily milking (TDM). Unilateral ODM of one udder half and TDM of the other half, enables the study of underlying mechanisms independently of inter-individual variability (same genetic background) and of environmental factors. Our results show that in first-calf heifers three CpG, located 10 kb upstream from the CSN1S1 gene were methylated to 33, 34 and 28%, respectively, after TDM but these levels were higher after ODM, 38, 38 and 33%, respectively. These methylation levels were much lower than those observed in the mammary gland during pregnancy (57, 59 and 50%, respectively) or in the liver (74, 78 and 61%, respectively). The methylation level of a fourth CpG (CpG4), located close by (29% during TDM) was not altered after ODM. CpG4 methylation reached 39.7% and 59.5%, during pregnancy or in the liver, respectively. CpG4 is located within a weak STAT5 binding element, arranged in tandem with a second high affinity STAT5 element. STAT5 binding is only marginally modulated by CpG4 methylation, but it may be altered by the methylation levels of the three other CpG nearby. Our results therefore shed light on mechanisms that help to explain how milk production is almost, but not fully, restored when TDM is resumed (15.1±0.2 kg/day instead of 16.2±0.2 kg/day, p<0.01). The STAT5 elements are 100 bp away from a region transcribed in the antisense orientation, in the mammary gland during lactation, but not during pregnancy or in other reproductive organs (ovary or testes). We now need to clarify whether the transcription of this novel RNA is a consequence of STAT5 interacting with the CSN1S1 distal region, or whether it plays a role in the chromatin structure of this region.
Collapse
Affiliation(s)
- Minh Nguyen
- INRA, UMR1313 Génétique Animale et Biologie Intégrative, Jouy-en-Josas, France
| | - Marion Boutinaud
- INRA, UMR1348 Physiologie Environnement et Génétique pour l′Animal et les Systèmes d′Elevage, Saint-Gilles, France
| | - Barbara Pétridou
- INRA, UMR1313 Génétique Animale et Biologie Intégrative, Jouy-en-Josas, France
| | - Anne Gabory
- INRA, UMR1198 Biologie du Développement et Reproduction, Jouy-en-Josas, France
| | - Maëlle Pannetier
- INRA, UMR1198 Biologie du Développement et Reproduction, Jouy-en-Josas, France
| | - Sophie Chat
- INRA, UMR1313 Génétique Animale et Biologie Intégrative, Jouy-en-Josas, France
| | - Stephan Bouet
- INRA, UMR1313 Génétique Animale et Biologie Intégrative, Jouy-en-Josas, France
| | - Luc Jouneau
- INRA, UMR1198 Biologie du Développement et Reproduction, Jouy-en-Josas, France
| | - Florence Jaffrezic
- INRA, UMR1313 Génétique Animale et Biologie Intégrative, Jouy-en-Josas, France
| | - Denis Laloë
- INRA, UMR1313 Génétique Animale et Biologie Intégrative, Jouy-en-Josas, France
| | - Christophe Klopp
- INRA, Sigenae, UR875 Biométrie et Intelligence Artificielle, Castanet-Tolosan, France
| | - Nicolas Brun
- INRA, UMR1313 Génétique Animale et Biologie Intégrative, Jouy-en-Josas, France
| | - Clémence Kress
- INSERM U846 Stem Cell and Brain Research Institute, INRA, USC1361 AGROBIOSYSTEM, Université de Lyon 1 UMR S 846, Bron, France
| | - Hélène Jammes
- INRA, UMR1198 Biologie du Développement et Reproduction, Jouy-en-Josas, France
| | - Madia Charlier
- INRA, UMR1313 Génétique Animale et Biologie Intégrative, Jouy-en-Josas, France
| | - Eve Devinoy
- INRA, UMR1313 Génétique Animale et Biologie Intégrative, Jouy-en-Josas, France
- * E-mail:
| |
Collapse
|
12
|
Ganss B, Abbarin N. Maturation and beyond: proteins in the developmental continuum from enamel epithelium to junctional epithelium. Front Physiol 2014; 5:371. [PMID: 25309457 PMCID: PMC4174742 DOI: 10.3389/fphys.2014.00371] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Accepted: 09/08/2014] [Indexed: 12/23/2022] Open
Abstract
Enamel, covering the surface of teeth, is the hardest substance in mammals. It is designed to last a lifetime in spite of severe environmental challenges. Enamel is formed in a biomineralization process that is essentially divided into secretory and maturation stages. While the molecular events of enamel formation during the secretory stage have been elucidated to some extent, the mechanisms of enamel maturation are less defined, and little is known about the molecules present beyond the maturation stage. Several genes, all located within the secreted calcium-binding phosphoprotein (SCPP) gene cluster, were recently shown to be expressed during the developmental continuum from maturation stage ameloblasts to junctional epithelium (JE). This review introduces four such genes and their protein products, and presents our current state of knowledge on their roles, primarily in enamel formation and JE biology. The discovery of these proteins, and a more detailed analysis of their biological functions, will likely contribute to a more thorough understanding of the molecular mechanisms of enamel maturation and dentogingival attachment.
Collapse
Affiliation(s)
- Bernhard Ganss
- Matrix Dynamics Group, Mineralized Tissue Lab, Faculty of Dentistry, University of Toronto Toronto, ON, Canada
| | - Nastaran Abbarin
- Matrix Dynamics Group, Mineralized Tissue Lab, Faculty of Dentistry, University of Toronto Toronto, ON, Canada
| |
Collapse
|
13
|
Gandhi SS, Kestler DP, Bruker CT, McLaughlin JM, Heidel RE, Siddiqui S, Foster JS, Gray KD, Bell J, Solomon A, Lewis J. Nuclear Odontogenic Ameloblast-Associated Protein (ODAM) Correlates with Melanoma Sentinel Lymph Node Metastasis. ACTA ACUST UNITED AC 2013. [DOI: 10.4236/jct.2013.48151] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|